[Flashglucose monitoring system (Freestyle Libre, Abbott), report updated April 8 2020]

N. Jobin, S. Arbour et al.
Record ID 32018000806
Original Title: Système flash de surveillance du glucose (FreeStyle Libre, Abbott), avis mise à jour 8 avril 2020
Authors' objectives: The Institut national d’excellence en santé et en services sociaux (INESSS), at the request of the ministère de la Santé et des Services sociaux (MSSS), evaluated the relevance of reimbursing Freestyle LibreMC (Abbott) flash glucose monitoring systems (FGMS) under the prescription drug insurance plan (RGAM). FGMS is a flash (or intermittent) real-time glucose level monitoring device. In Canada, its current indication is approved for measuring the glucose from interstitial fluids in adults of at least 18 years of age with at least two (2) years of experience in diabetes selfmanagement.
Authors' recommendations: The Institut national d’excellence en santé et en services sociaux (INESSS), considering all the criteria laid down by law, recommends to the Minister of Health and Social Services to enter FreeStyle LibreMC on the list of the prescription drug insurance plan (RGAM) for blood glucose self-monitoring for patients under insulin treatment, provided that the following condition is met. Condition Easing the economic burden If the economic burden is not lessened, the INESSS recommends to enter FreeStyle LibreMC on the list of exception drugs in accordance with the proposed recognized payment indication.
Authors' methods: Prior to delivering this notice, a systematic review of relevant literature was completed to identify evidence-based findings needed for assessing and completing the information provided by the manufacturer. Then, panels of patients (users and non-users of the technology in question) and clinicians with expertise in diabetes management were set up for gathering experiential and contextual data to help understand various viewpoints on FGMS; hence, criteria for diversifying the individuals to be consulted were defined and established for each panel to highlight potential advantages, disadvantages and concerns linked to FGMS use. Also, an economic evaluation and a budget impact analysis were conducted. All the data gathered and delivered by the project team was submitted to the Standing Scientific Committee on Entry on the List of Medications (CSEMI) for deliberation on therapeutic values of the FGMS prior to formulating recommendations.
Project Status: Completed
Year Published: 2018
Requestor: Minister of Health
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
Province: Quebec
MeSH Terms
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Blood Glucose
  • Blood Glucose Self-Monitoring
  • Diabetes Mellitus
  • Adult
  • Hypoglycemia
  • Diabetes
Organisation Name: Institut national d'excellence en sante et en services sociaux
Contact Address: L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name: demande@inesss.qc.ca
Contact Email: demande@inesss.qc.ca
Copyright: Gouvernement du Québec
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.